Innocan Pharma Reports Q3 2023 Results
HERZLIYA, Israel, and CALGARY, Alberta — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property portfolio, is pleased to announce its financial results for the three and nine months period ended September 30, 2023. “We are thrilled with the significant growth we achieved in the third quarter,” says Iris Bincovich, CEO of Innocan. “Our strategic focus on the midterm-goal of FDA approvals for our LPT-CBD-loaded liposome platform, alongside the robust sales from our subsidiary, B.I. Sky Global Ltd., have significantly contributed to this increase in both revenue and gross profit. We remain committed to our vision and are optimistic about the future.” Financial highlights for the third quarter of 2023 Revenue: The Company posted US$4.083M in revenue for the three months ended September 30, 2023, marking an increase of U...